Research & Development Services
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral diseases: COVID-19 and influenza, two disease areas with urgent need for effective therapeutics.
-
Most popular related searches
Details
Preclinical studies have proven the antiviral efficacy of zapnometinib against various strains of influenza virus, hantavirus and respiratory syncytial virus (RSV). These promising data led to a Phase I clinical study with 70 healthy volunteers, which was successfully conducted in 2019 and demonstrated excellent safety and tolerability of zapnometinib (NCT04385420). In addition, pharmacokinetics exposure and determination of MEK inhibition were verified and confirmed the maintenance of clinically relevant blood levels. This supports the intended once-daily regime for the ongoing Phase II clinical development.
Customer reviews
No reviews were found for Research & Development Services. Be the first to review!